Reply to Abildgaard et al.: lot variation and inter-device differences contribute to poor analytical performance of the DCA vantage™ HbA1cPOCT instrument in a true clinical setting

What is it about?

The article published by Abildgaard et al. suggested that HbA1c assay on the DCA Vantage analyzer does not meet analytical performance requirements and undermines the utility of point of care HbA1c testing. This reply highlights several limitations of the study presented and argues against their conclusions. It provides evidence of strong analytical performance with the DCA Vantage analyzer and demonstrates the usefulness of point of care HbA1c testing.

Featured Image